Corcept Therapeutics Incorporated (CORT)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	106,140	101,418	112,512	106,011	94,181
Total stockholders’ equity	US$ in thousands	506,705	501,842	375,806	523,338	371,182
ROE		20.95%	20.21%	29.94%	20.26%	25.37%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $106,140K ÷ $506,705K
= 20.95%

Corcept Therapeutics Inc has maintained a relatively stable return on equity (ROE) over the past five years, ranging from 20.21% to 29.94%. The ROE for the most recent year, as of December 31, 2023, stands at 20.95%, indicating that for every dollar of shareholders' equity, the company generated a return of 20.95 cents in net income.

Although the ROE has exhibited fluctuations, it has generally remained above 20% over the period under review, suggesting that the company effectively utilizes its equity to generate profits. The decline in ROE from 29.94% in 2021 to 20.26% in 2020 followed by another increase in 2019 may indicate varying levels of profitability and efficiency in capital utilization during those years.

Overall, the consistent ROE above 20% reflects positively on Corcept Therapeutics Inc's ability to generate earnings from shareholders' equity, indicating a strong profitability and efficiency in utilizing its resources to create value for its investors.